VICTRELIS Drug Patent Profile

Which patents cover Victrelis, and when can generic versions of Victrelis launch?

Victrelis is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

DrugPatentWatch^® Generic Entry Outlook for Victrelis

Victrelis was eligible for patent challenges on May 13, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 11, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VICTRELIS

International Patents:	27
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	9
Patent Applications:	2,692
DailyMed Link:	VICTRELIS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VICTRELIS

Constraining patent/regulatory exclusivity:

7,772,178

NDA:

202258

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VICTRELIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoffmann-La Roche
University Medical Center Groningen	Phase 2
Rijnstate Hospital	Phase 2

See all VICTRELIS clinical trials

US Patents and Regulatory Information for VICTRELIS

VICTRELIS is protected by two US patents.

This potential generic entry date is based on patent 7,772,178.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	7,772,178		Y
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	8,119,602

Expired US Patents for VICTRELIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	7,012,066
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	RE43298

EU/EMA Drug Approvals for VICTRELIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp Dohme Ltd	Victrelis	boceprevir	EMEA/H/C/002332Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.	Withdrawn	no	no	no	2011-07-18

International Patents for VICTRELIS

When does loss-of-exclusivity occur for VICTRELIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VICTRELIS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2004504404
Colombia	5650168	NUEVOS PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3 DEL VIRUS DE LA HEPATITIS C
Canada	2611155	FORMULATIONS PHARMACEUTIQUES ET METHODES DE TRAITEMENT UTILISANT CES FORMULATIONS (COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT)
Luxembourg	91910

Supplementary Protection Certificates for VICTRELIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1385870	C01385870/01	Switzerland		PRODUCT NAME: BOCEPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 62105 31.10.2011
1385870	C300506	Netherlands		PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROATMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1385870	SPC/GB11/057	United Kingdom		PRODUCT NAME: BOCEPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/704/001 20110720
1385870	C 2011 014	Romania		PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718

Market Dynamics and Financial Trajectory for VICTRELIS (Boceprevir)

Last updated: January 3, 2026

Executive Summary

VICTRELIS (boceprevir) was a groundbreaking hepatitis C virus (HCV) protease inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2011. Developed by Merck & Co., it represented one of the first directly acting antivirals (DAAs) targeting HCV genotype 1, significantly altering the treatment landscape. However, rapid technological advances, market competition, and evolving treatment paradigms have dramatically transformed its commercial prospects. This analysis explores the market dynamics and financial trajectory of VICTRELIS, considering patent markets, competitive threats, regulatory shifts, and shifting demand patterns from launch to decline.

---

What Are the Key Market Factors Influencing VICTRELIS’s Trajectory?

1. Market Introduction and Initial Adoption

• Regulatory Milestones:
  Approved by the FDA on May 13, 2011, VICTRELIS was launched as part of a combination regimen with pegylated interferon (Peg-IFN) and ribavirin, marking a significant advancement in HCV treatment.

• Competitive Landscape at Launch:
  Competed primarily with Incivek (telaprevir, Johnson & Johnson/Vertex) and traditional interferon-based therapies. Initial uptake was driven by its enhanced efficacy, with sustained virologic response (SVR) rates up to 75% for genotype 1.

• Market Penetration:
  In its first years, VICTRELIS captured a substantial share of the HCV antiviral segment, with peak sales reaching approximately $750 million globally in 2012-2013.

2. Patent Status and Market Exclusivity

Patent/Regulatory Milestone	Date	Notes
US Patent Grant	2011	Patent expected to extend until at least 2021-2023, depending on jurisdictional extensions.
Market Exclusivity	2011-2016	Initially protected, but patents faced challenges as generics and biosimilar threats emerged.

• Patent Challenges:
  Due to patent expirations and potential generic entry, Merck faced increased competition by mid-decade.

3. Competition and Market Saturation

Competitors	Key Features	Market Impact	Notes
Incivek (telaprevir)	Similar mechanism, launched 2011	Directly competed, leading to market share erosion for VICTRELIS
Newer DAAs (e.g., Sovaldi, Harvoni)	Shorter regimens, higher cure rates	Rapidly supplanted VICTRELIS as standard of care from 2014 onwards
Generic VICTRELIS	Pending patent expiry	Introduced after patent challenges, reducing revenue

• Shift to All-Oral Regimens:
  The arrival of highly effective, interferon-free oral therapies like Sovaldi (sofosbuvir, Gilead, 2013) and Harvoni (sofosbuvir/ledipasvir, Gilead, 2014) caused a fundamental shift away from interferon-based regimens, curbing VICTRELIS sales.

4. Regulatory and Policy Shifts

• Guideline Updates (2014+):
  Leading agencies, including the American Association for the Study of Liver Diseases (AASLD), revised treatment algorithms favoring all-oral DAA combinations, diminishing VICTRELIS’s usage.

• Pricing and Reimbursement:
  Rebate pressures, insurance payor restrictions, and pricing battles further limited market penetration over time.

5. Demand Trends and Patient Preferences

Phase	Market Dynamics	Forecasted Impact
2011-2013	Rapid adoption, high demand	Initial revenue peak (~$750M)
2014-2016	Decline as newer therapies entered	Revenue decline (~50% annually)
2017+	Niche and generic markets	Minimal or no sales

---

Financial Trajectory Analysis

1. Revenue Trends

Year	Estimated Global Sales	Source/Notes
2011	~$300 million	Launch year, initial uptake)
2012	~$750 million	Peak sales, increased adoption
2013	~$600 million	Slight decline, market saturation
2014	~$250 million	Competition intensifies, early emergence of new DAAs
2015-2016	<$50 million	Rapid decline due to alternatives
2017+	Negligible	Market essentially phased out

Note: Exact figures vary across estimates; Merck’s annual reports and IQVIA data provide details.

2. Cost and Profitability Dynamics

• Research & Development (R&D) Investment:
  Estimated at ~$1.2 billion during discovery and development phases [1].

• Pricing Strategy:
  Launched at approximately $66,000 for a 48-week course, with discounts and rebates reducing the net price.

• Profit Margins:
  Initially high, but rapidly compressed post-2014 due to competition and patent disputes.

3. Patent Expiry and Market Entry of Generics

• Patent Expiration:
  US patent expired around 2018-2019, enabling biosimilar and generic entrance.

• Impact:
  Significant price erosion, further constraining profitability and sales.

---

Comparative Analysis: VICTRELIS vs. Next-Generation DAAs

Parameter	VICTRELIS (Boceprevir)	Sovaldi (Sofosbuvir)	Harvoni (Sofosbuvir/Ledipasvir)
Approval Year	2011	2013	2014
Treatment Regimen	Peg-IFN + RBV + boceprevir	Interferon + RBV	Interferon-free, oral
SVR Rate	66-75%	90-95%	94-99%
Duration	24-48 weeks	12-24 weeks	8-12 weeks
Cost	~$66,000/course	~$84,000 (initial), later lower	~$74,000 (initial)
Market Impact	Major initial revenue, rapid decline	Market leader	Supplants earlier drugs

How Does the Evolving Pipeline Affect VICTRELIS?

Constant innovations and efficacy enhancements in DAAs resulted in shortened, simpler regimens, effectively rendering VICTRELIS obsolete in most markets. The rapid decline underscores a pattern prevalent across the pharmaceutical landscape: early breakthroughs are often superseded by superior therapies.

---

Market Outlook and Strategic Considerations

Is there still a niche for VICTRELIS?

• Limited to pharmaceutical markets with specific genotypes or resistance profiles.
• Potential use in combination with other agents in certain refractory cases.
• Remaining patent protection in select jurisdictions may sustain minimal revenue streams temporarily.

What are the key challenges facing VICTRELIS’s future?

Challenge	Description	Mitigation Strategies
Patent expiration	Loss of exclusivity	Seek patent extensions or new indications
Competition from oral DAAs	Superior efficacy and tolerability	Focus on niche markets, combination therapies
Regulatory shifts	Preferability for all-oral, interferon-free regimens	Redirection to specialized uses

---

Key Takeaways

• Initial Success: VICTRELIS marked a pivotal moment in HCV therapy, achieving peak sales of approximately $750 million in 2012.
• Market Saturation & Obsolescence: The advent of all-oral, highly effective DAAs resulted in rapid decline—sales plummeted within three years.
• Patent and Generic Impact: Patent expiry in 2018-2019 precipitated price erosion and further revenue contraction.
• Therapeutic Evolution: Shifts in treatment guidelines favored interferon-free regimens, rendering VICTRELIS largely obsolete.
• Future Potential: Limited niche applications may sustain residual demand, but large-scale market presence is unlikely.

---

FAQs

1. Why was VICTRELIS initially considered a breakthrough?
It was among the first protease inhibitors targeting HCV genotype 1, significantly improving cure rates over interferon-based therapies when combined with pegylated interferon and ribavirin.

2. How does VICTRELIS compare to newer DAA therapies?
Newer DAAs, like sofosbuvir and ledipasvir, offer higher SVR rates, shorter treatment durations (8-12 weeks), oral administration without interferon, and fewer side effects, making VICTRELIS largely obsolete.

3. When did VICTRELIS's patent protections expire, and what was the impact?
The primary US patent expired around 2018, enabling generic imports and leading to substantial price reductions, further diminishing commercial viability.

4. Is VICTRELIS still recommended in any treatment protocols?
Its use is virtually discontinued; current guidelines favor all-oral DAA regimens. VICTRELIS may have limited roles in select, resistant HCV cases or specific research settings.

5. What lessons can pharmaceutical companies learn from VICTRELIS's trajectory?
Early innovation must be sustained with ongoing R&D to adapt to market shifts. Patents and exclusivity are temporary; continuous pipeline updates and strategic patent management are essential for long-term viability.

---

References

[1] Merck & Co. Annual Reports and SEC Filings, 2011-2016.
[2] US FDA, VICTRELIS (boceprevir) approval documents, 2011.
[3] IQVIA data on hepatitis C drugs, 2012-2019.
[4] American Association for the Study of Liver Diseases (AASLD) guidelines, 2014-2022.
[5] Market analyses from EvaluatePharma, 2012-2019.

---

This comprehensive view underscores the rapid evolution in the hepatitis C treatment market, illustrating how a pioneering drug like VICTRELIS can swiftly transition from blockbuster to niche, driven by technological innovation and strategic market shifts.